Dr Barili updating meta-analysis from last year - TAVI and SAVR

#EACTS2020
Major updates in data from randomized trials. 5 yr follow-up now doubled!
#EACTS2020
7 trials included with 1 yr data
#EACTS2020
HR 1.00 at 5 yrs. But: proportional hazards assumption not met, so landmark analysis necessary
#EACTS2020
Landmark analysis: 0-24 months HR 0.77 favoring TAVI, 24-48 months HR 1.18 favoring SAVR
#EACTS2020
HR varies over time - reversal after 2 yrs
#EACTS2020
Conclusions: TAVI has survival for 2 yrs, reversal after 2 yr
#EACTS2020

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Patrick Myers

Patrick Myers Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @pomyers

10 Oct
@kaulcsmc discussing TAVI in low-risk patients
Disclosure: from an impartial observer
#EACTS2020
Current recommendations for TAVR
#EACTS2020
Trial design in TAVI
Total number of total primary outcome events 4x lower in low-risk trial for Sapien. CoreValve more robust by design, yet events 2.5x lower and 2yr follow-up computed.
#EACTS2020
Read 11 tweets
10 Oct
@BavariaMd giving insights of TVT registry on TAVI
#EACTS2020
Importance of registries
#EACTS2020
Numbers in TVT: ViV represents 6-7%; TAVR
#EACTS2020
Read 13 tweets
10 Oct
SYNTAX score is an angiographic score of angiographic complexity
Designed to predict feasibility of PCI - nothing to do with feasibility of CABG or outcomes
#EACTS2020
It may prove actually wrong for CABG: a CTO can easily be grafted, yet prediction by SYNTAX would suspect bad outcome.
#EACTS2020
Read 10 tweets
17 Jul
After almost 1 year, the wait is over - the #EXCEL investigators finally release the UDMI data in @NEJM
nejm.org/doi/full/10.10…
🧵 in a nutshell:
- the EXCEL investigators had the UDMI data, although they said they didn’t
- It shows higher MI risk for PCI
- This is research fraud and the papers should be retracted

@BBCnewsnight have had this data since december, why did it take 7 months more? Gosh @NEJM, what is up?
/2
Main finding: PCI has 2x the incidence of PMI (95%CI: 0.5-3.3), and 4.9x the incidence of all MI when using UDMI (95%CI: 2.6-7.2)

/3
Read 25 tweets
3 Feb
PVL is decreasing with improving sizing and devices in TAVR. I definitively have this impression from my practice. Or is it really? 1/11
2/ @VictorDayan1 showed in October that the criteria for PVL weren’t the same between PARTNER2 and PARTNER3

3/ VARC-II criteria define mild PVL as circumferential extent <10% and regurgitant volume of <30%.

academic.oup.com/ejcts/article/… Image
Read 12 tweets
2 Oct 19
After a few days to go over the #EXCEL 5 year results published in @NEJM and thinking hard about @DrMoritzWvB tweet on IC and cardiac surgery seeing things quite differently, here are a few thoughts. Glad to hear your thoughts
@tssmn @ctsnetorg @EACTS
1/30
2/ Congratulations to the investigators for an outstanding RCT! Important question and results, which will have an impact on guidelines. The protocol was powered for non-inferiority of the composite outcome at 3 years, and congratulations for following these patients to 5 years
3/ why were p-values for secondary outcomes reported selectively? e.g. for revascularization, but not others?
Read 34 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!